Sales Force Size Continues Up--Or Does It?
While some companies have seen dramatic increases in the last year-at least half of the companies with more than 1050 reps have decreased the size of their forces since 1995, including BMS, at least prior to its most recent announcement.
You may also be interested in...
Pfizer's big sales force cuts mark the beginning of a disarmament in sales infrastructure across the pharmaceutical industry. That means a lot of sales reps will be out of work-and looking for payback.
Access to expedited regulatory pathways, marketing exclusivity and tax credits in exchange for enrolling and retaining diverse clinical trial populations could provide a ‘carrot’ to the ‘stick’ in US FDA guidance and legislative proposals; attorneys Sarah Thompson Schick and Winston Kirton also call for a re-examination of concerns about remuneration for trial participants.
CBER Director Peter Marks said more sophisticated manufacturing expected in the next decade could lead to questions about whether gene therapies should be regulated by his center or CDRH.